This page is an automatically generated summary of information from the Federal Court, Federal Court of Appeal, Health Canada and other websites. This information should NOT be relied upon as it is automatically generated and has not been confirmed for accuracy.
Automatically generated on November 4, 2024.
Return to the list of Patented Medicine Litigation page.
Empagliflozin
GLYXAMBI, JARDIANCE, SYNJARDY – BOEHRINGER INGELHEIM (CANADA) LTD LTEE (NOC Search)
Patents:
- 2443937: SANDOZ
- 2443945: SANDOZ
- 2557801: APOTEX, JAMP, SUN PHARMA, SANDOZ
- 2606650: APOTEX, SUN PHARMA, JAMP, SANDOZ
- 2696558: SANDOZ, SUN PHARMA, JAMP, TEVA, APOTEX
- 2751833: SANDOZ, JAMP, SUN PHARMA, TEVA, APOTEX
- 2752435: APOTEX, SANDOZ, JAMP, SUN PHARMA
- 2813661: APOTEX, SANDOZ, JAMP, SUN PHARMA, TEVA
- 2909728: TEVA
APOTEX
- PM(NOC) – T-641-23
JAMP
- PM(NOC) – T-2276-22 (2023 FC 943, 2023 CanLII 125709) – T-2318-22
SANDOZ
- PM(NOC) – T-1831-22 (2023 FC 1149, 2023 FC 1175, 2023 FC 241)
SUN PHARMA
- PM(NOC) – T-1842-22
TEVA
- PM(NOC) – T-2953-24
Return to the Patented Medicine Litigation page.